Cleave Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia, in RelapseMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Cleave Therapeutics, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04402541
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸KU Clinical Research Center, Fairway, Kansas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
News
No news found